Overview

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy of Oral azacitidine versus single-agent Investigator's Choice Therapy in patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Collaborator:

Celgene

Treatments:

Azacitidine
Bendamustine Hydrochloride
Gemcitabine
Romidepsin